Any prescribed medication may be covered, depending on your plan
GLOBAL GLUTATHIONE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION) TABLE 132
IGF-1 LR3 in a research protocol effectively provides supraphysiological systemic IGF1R activation without going through either the hepatic or the local production pathway
Expected 12-month results include 15 to 22% body weight loss (50 to 75 pounds for a 300-pound person), 5 to 8 inch waist circumference reduction, major improvement in mobility and physical function, and often dramatic improvement or resolution of obesity-related health conditions including sleep apnea, fatty liver disease, and joint pain
This is documented in the foundational study: a peer-reviewed randomized placebo-controlled trial in JAIDS evaluating Tesamorelins effects in patients with abdominal fat accumulation, including the safety extension data showing sustained visceral fat reduction with continued therapy